ITC, Dr. Agarwal’s, Gland Pharma and SRF feature among the top names that were upgraded by Jefferies during or after the June quarter results season, …
1/11ITC, Dr. Agarwal’s, Gland Pharma and SRF feature among the top names that were upgraded by Jefferies during or after the June quarter results season, while Syrma SGS, Muthoot Finance, GAIL, IKS Health, Aegis Vopak were all downgraded by the brokerage during the same timeframe to “hold” from the earlier rating of “buy”. Here are more details:
2/11ITC | Jefferies upgraded ITC to “buy” from its earlier rating of “hold” on August 3, with a price target of ₹350 apiece. This implies an upside of 31% from its previous close. Of the 38 analysts who have coverage on the stock, 20 have a “buy” rating, 15 have a “hold” rating and three have a “sell” rating. Shares of ITC are currently trading 0.2% higher at ₹267.6. The stock is still down 26% so far this year.
3/11Dr Agarwal’s Health Care | Jefferies has upgraded the stock to “buy” as well from “hold” on August 5, with a target of ₹600 per share, indicating an upside of 19.6% from its previous close. A total of five analysts have coverage on the stock and all of them have a “buy” rating. Shares of Dr. Agarwal’s healthcare are now trading 0.3% lower at ₹499.5. The stock has remained flat all through the year.
4/11Gland Pharma | Jefferies earlier had a “hold” rating on the stock, which was then upgraded to “buy” on August 11. It has a target of ₹3,350 per share on the stock, indicating an upside of 17.9% from current levels. Of the 18 analysts who have coverage on the stock, 11 have a “buy” rating, three have a “hold” rating and four have a “sell” rating. Shares of Gland Pharma are trading 0.4% lower at ₹2,829.9. The stock has risen 65% so far this year.
5/11SRF | Jefferies has upgraded the stock to “hold” from “underperform” and has a target price of ₹2,540 per share, which is 1.5% lower than its previous close. Of the 33 analysts who have coverage on the stock, 21 have a “buy” rating, five have a “hold” rating and eight have a “sell” rating. SRF shares were trading flat at ₹2,581 apiece at 11.05 am on Thursday. It has declined 10.1% in the past month and is down 15.6% this year, so far.
6/11Syrma SGS Technology | The brokerage has downgraded the stock to “hold” from “buy”. It has a target price of ₹1,430 per share, which is 4.3% lower than its previous close. A total of 29 analysts have coverage on the stock. Of them, 22 have a “buy” rating, six have a “hold” rating and one has a “sell” rating. The stock is trading 0.5% lower at ₹1,487.5. The stock has more than doubled in value so far this year, gaining 106%.
7/11Muthoot Finance | Jefferies now has a “hold” rating on the stock from its previous “underperform” rating and a target price of ₹3,300 per share. This implies an upside of 15.4% from its previous close. Of the 26 analysts who have coverage on the stock, 14 have a “buy” rating, seven have a “hold” rating and five have a “sell” rating. Shares of Muthoot Finance are trading 4.6% higher on Thursday at ₹2,991.1. The stock is still down 22% so far this year.
8/11GAIL India | Jefferies has downgraded the stock to “hold” from “buy” and has a target price of ₹185 per share, an upside of 7.2% from its previous close. Of the 32 analysts who have coverage on the stock, 21 have a “buy” rating, nine have a “hold” rating and two have a “sell” rating. Shares of GAIL are trading 0.3% higher on Thursday at ₹173. The stock has remained flat through the year so far.
9/11Inventurus Knowledge Solutions | Jefferies has downgraded the stock to “hold” as well from “buy” and has a target price of ₹1,860 per share on it. This is 2.6% higher than the previous closing price. A total of seven analysts have “buy” recommendations on the stock while two have “hold” ratings. Shares of IKS Health are trading 1.8% lower on Thursday at ₹1,780. The stock has risen 12% over the last one year.
10/11Aegis Vopak Terminals | Jefferies has downgraded the stock to “hold” from “buy” and has a target price of ₹280 per share, which is 3.6% higher than its previous close. Barring Jefferies, the other two analysts have coverage on the stock have “buy” recommendations. Shares of Aegis Vopak are trading 0.3% lower on Thursday at ₹269.2. The stock is up 7% so far this year.
11/11Hexaware Technologies | Jefferies has downgraded the stock to “underperform” from “hold” and has a target price ₹500 per share, a downside of 9.6% from its previous close. Of the 17 analysts who have coverage on the stock, 10 have a “buy” rating, three have a “hold” rating and four have a “sell” rating. Shares have declined 27% so far this year.
